Group 1 - The company has initiated its fourth share repurchase program, with a total expected amount between 50 million and 100 million RMB [1][2] - The repurchase period is set from May 12, 2025, to May 11, 2026, and the maximum repurchase price is capped at 13 RMB per share [1][2] - As of the end of June 2025, the company has repurchased a total of 5,535,000 shares, representing 0.46% of the total share capital, with a total expenditure of 50,891,385 RMB [2] Group 2 - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] - The highest purchase price recorded during the repurchase was 9.40 RMB per share, while the lowest was 8.92 RMB per share [2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [2]
海正药业: 浙江海正药业股份有限公司关于第四次以集中竞价交易方式回购公司股份的进展公告